1
NR565 Week 8 Final Exam: 26th June 2026 Summer NR
565 Advanced Pharmacology Fundamentals Complete
Question 1- 100 (Actual Exam Proctored via Examplify)
With Correct Answers | 100% Pass Guaranteed |
Graded A+
NR565 Week 8 Final Exam | Summer 2026
Course: NR 565 Advanced Pharmacology Fundamentals
Date: 26th June 2026
Proctoring: Examplify
Total Questions: 100 | Passing Standard: Graded A+ Threshold (Advanced Clinical
Reasoning)
Instructions: This examination is designed to test the application of
pharmacotherapeutics in complex clinical scenarios. You will encounter patients
with comorbidities, polypharmacy, and nuanced treatment guidelines. Select
the BEST or MOST APPROPRIATE answer. Assume standard adult dosing unless
pediatric or geriatric parameters are specified.
Section 1: Thyroid Disorders (Questions 1-10)
1. A 32-year-old female with Graves' disease is started on Methimazole. Six
weeks into therapy, she presents with a fever of 102.4°F and severe sore
throat. Her heart rate is 110 bpm but regular. What is the most
critical immediate action?
o A. Prescribe Amoxicillin for streptococcal pharyngitis and schedule
follow-up in 48 hours.
pg. 1
,2
o B. Order STAT CBC with differential and instruct patient to
discontinue Methimazole until results are known.
o C. Increase Methimazole dose to address potential thyroid storm
precipitating the fever.
o D. Switch to Propylthiouracil (PTU) immediately as this is a known
hypersensitivity reaction to Methimazole.
Answer: B. Order STAT CBC with differential and instruct patient to
discontinue Methimazole until results are known.
• • • Rotation: The scenario describes the classic
presentation of Agranulocytosis (fever + sore throat). This is the most
dangerous toxicity of Methimazole. While rare (<0.5%), it is life-
threatening. The correct action is Stop Drug -> Stat CBC. Option A is
dangerous; assuming Strep and prescribing Amoxicillin masks the true bone
marrow failure. Option C is lethal; increasing dose worsens
suppression. Option D is incorrect; PTU also causes agranulocytosis (and
severe hepatotoxicity). The NP must differentiate this from benign viral
URI; a CBC is non-negotiable.
2. The NP is initiating Levothyroxine in a 68-year-old patient with a history of
Atrial Fibrillation and stable Coronary Artery Disease (CAD). Current TSH is
12 mIU/L. Which initiation strategy is most appropriate to prevent
iatrogenic cardiac decompensation?
o A. Initiate full replacement dose of 1.6 mcg/kg/day to normalize TSH
rapidly and reduce cardiovascular risk.
o B. Initiate therapy at 12.5-25 mcg/day and titrate slowly every 6-8
weeks based on TSH and clinical cardiac status.
o C. Initiate therapy with Liothyronine (T3) only, as T4 conversion is
impaired in CAD patients.
o D. Hold Levothyroxine until the patient undergoes elective
cardioversion for the Atrial Fibrillation.
pg. 2
,3
Answer: B. Initiate therapy at 12.5-25 mcg/day and titrate slowly
every 6-8 weeks.
• • • Rotation: "Start Low, Go Slow" is the mantra in
elderly cardiac patients. Full replacement (Option A) increases
myocardial oxygen demand (inotropy/chronotropy) and can
precipitate Myocardial Infarction or Atrial Fibrillation with
RVR. Option C (Liothyronine) is not first-line and has higher cardiac
risk. Option D is mismanagement; untreated hypothyroidism worsens
lipids and CAD. The big rotation here is
recognizing Pharmacodynamic Iatrogenesis: correcting a deficiency
too quickly in a sensitive host causes more harm than the disease.
3. A patient on Warfarin for DVT prophylaxis is newly diagnosed with
hypothyroidism and started on Levothyroxine. What is the anticipated
pharmacokinetic interaction and required monitoring adjustment?
o A. Levothyroxine inhibits CYP2C9; Warfarin levels will rise; decrease
Warfarin dose preemptively.
o B. Levothyroxine increases the catabolism of Vitamin K-dependent
clotting factors; INR will rise significantly; monitor INR weekly.
o C. Restoration of metabolic rate increases clotting factor turnover;
Warfarin dose may need to be increased due to increased clearance
of clotting factors.
o D. Levothyroxine binds to albumin displacing Warfarin; INR will spike
acutely for 48 hours post-dose.
Answer: C. Restoration of metabolic rate increases clotting factor
turnover; Warfarin dose may need to be INCREASED.
• • • Rotation: This is a classic NP boards trap.
Hypothyroidism slows metabolism. Warfarin clotting factors (II, VII, IX,
X) degrade slower, making patients more sensitive to Warfarin (lower
dose needed). Once Levothyroxine restores normal metabolism,
pg. 3
, 4
clotting factor degradation accelerates, requiring a HIGHER dose of
Warfarin to maintain same INR. Option B describes the reverse
scenario (starting thyroid hormone makes the INR go UP initially? No,
that's wrong; it goes down over weeks). This is
a Pharmacokinetic/Physiologic Antagonism.
4. A 28-year-old female with Graves' disease is 6 weeks pregnant and
experiencing severe hyperthyroidism symptoms. She requests medication
to control her symptoms. What is the guideline-based pharmacologic
approach?
o A. Methimazole is preferred throughout pregnancy due to lower
hepatotoxicity risk.
o B. Propylthiouracil (PTU) is preferred in the first trimester due to
lower risk of embryopathy.
o C. Radioactive Iodine (I-131) is safe as the fetal thyroid is inactive
until week 20.
o D. No treatment is needed; hyperthyroidism is protective in
pregnancy and does not cross the placenta.
Answer: B. Propylthiouracil (PTU) is preferred in the first trimester
due to lower risk of embryopathy.
• • • Rotation: Teratogenicity Risk Stratification.
o First Trimester: PTU. Methimazole is associated with
"Methimazole Embryopathy" (Choanal atresia, aplasia cutis). The
FDA and ATA recommend PTU for the first 16 weeks.
o Second/Third Trimester: Switch to Methimazole. PTU carries
a Black Box Warning for severe hepatotoxicity, which is more
dangerous to the mother later in pregnancy.
o Option A is wrong; Methimazole is avoided early. Option C is
wrong; RAI is ABSOLUTELY contraindicated in pregnancy
(ablates fetal thyroid).
pg. 4
NR565 Week 8 Final Exam: 26th June 2026 Summer NR
565 Advanced Pharmacology Fundamentals Complete
Question 1- 100 (Actual Exam Proctored via Examplify)
With Correct Answers | 100% Pass Guaranteed |
Graded A+
NR565 Week 8 Final Exam | Summer 2026
Course: NR 565 Advanced Pharmacology Fundamentals
Date: 26th June 2026
Proctoring: Examplify
Total Questions: 100 | Passing Standard: Graded A+ Threshold (Advanced Clinical
Reasoning)
Instructions: This examination is designed to test the application of
pharmacotherapeutics in complex clinical scenarios. You will encounter patients
with comorbidities, polypharmacy, and nuanced treatment guidelines. Select
the BEST or MOST APPROPRIATE answer. Assume standard adult dosing unless
pediatric or geriatric parameters are specified.
Section 1: Thyroid Disorders (Questions 1-10)
1. A 32-year-old female with Graves' disease is started on Methimazole. Six
weeks into therapy, she presents with a fever of 102.4°F and severe sore
throat. Her heart rate is 110 bpm but regular. What is the most
critical immediate action?
o A. Prescribe Amoxicillin for streptococcal pharyngitis and schedule
follow-up in 48 hours.
pg. 1
,2
o B. Order STAT CBC with differential and instruct patient to
discontinue Methimazole until results are known.
o C. Increase Methimazole dose to address potential thyroid storm
precipitating the fever.
o D. Switch to Propylthiouracil (PTU) immediately as this is a known
hypersensitivity reaction to Methimazole.
Answer: B. Order STAT CBC with differential and instruct patient to
discontinue Methimazole until results are known.
• • • Rotation: The scenario describes the classic
presentation of Agranulocytosis (fever + sore throat). This is the most
dangerous toxicity of Methimazole. While rare (<0.5%), it is life-
threatening. The correct action is Stop Drug -> Stat CBC. Option A is
dangerous; assuming Strep and prescribing Amoxicillin masks the true bone
marrow failure. Option C is lethal; increasing dose worsens
suppression. Option D is incorrect; PTU also causes agranulocytosis (and
severe hepatotoxicity). The NP must differentiate this from benign viral
URI; a CBC is non-negotiable.
2. The NP is initiating Levothyroxine in a 68-year-old patient with a history of
Atrial Fibrillation and stable Coronary Artery Disease (CAD). Current TSH is
12 mIU/L. Which initiation strategy is most appropriate to prevent
iatrogenic cardiac decompensation?
o A. Initiate full replacement dose of 1.6 mcg/kg/day to normalize TSH
rapidly and reduce cardiovascular risk.
o B. Initiate therapy at 12.5-25 mcg/day and titrate slowly every 6-8
weeks based on TSH and clinical cardiac status.
o C. Initiate therapy with Liothyronine (T3) only, as T4 conversion is
impaired in CAD patients.
o D. Hold Levothyroxine until the patient undergoes elective
cardioversion for the Atrial Fibrillation.
pg. 2
,3
Answer: B. Initiate therapy at 12.5-25 mcg/day and titrate slowly
every 6-8 weeks.
• • • Rotation: "Start Low, Go Slow" is the mantra in
elderly cardiac patients. Full replacement (Option A) increases
myocardial oxygen demand (inotropy/chronotropy) and can
precipitate Myocardial Infarction or Atrial Fibrillation with
RVR. Option C (Liothyronine) is not first-line and has higher cardiac
risk. Option D is mismanagement; untreated hypothyroidism worsens
lipids and CAD. The big rotation here is
recognizing Pharmacodynamic Iatrogenesis: correcting a deficiency
too quickly in a sensitive host causes more harm than the disease.
3. A patient on Warfarin for DVT prophylaxis is newly diagnosed with
hypothyroidism and started on Levothyroxine. What is the anticipated
pharmacokinetic interaction and required monitoring adjustment?
o A. Levothyroxine inhibits CYP2C9; Warfarin levels will rise; decrease
Warfarin dose preemptively.
o B. Levothyroxine increases the catabolism of Vitamin K-dependent
clotting factors; INR will rise significantly; monitor INR weekly.
o C. Restoration of metabolic rate increases clotting factor turnover;
Warfarin dose may need to be increased due to increased clearance
of clotting factors.
o D. Levothyroxine binds to albumin displacing Warfarin; INR will spike
acutely for 48 hours post-dose.
Answer: C. Restoration of metabolic rate increases clotting factor
turnover; Warfarin dose may need to be INCREASED.
• • • Rotation: This is a classic NP boards trap.
Hypothyroidism slows metabolism. Warfarin clotting factors (II, VII, IX,
X) degrade slower, making patients more sensitive to Warfarin (lower
dose needed). Once Levothyroxine restores normal metabolism,
pg. 3
, 4
clotting factor degradation accelerates, requiring a HIGHER dose of
Warfarin to maintain same INR. Option B describes the reverse
scenario (starting thyroid hormone makes the INR go UP initially? No,
that's wrong; it goes down over weeks). This is
a Pharmacokinetic/Physiologic Antagonism.
4. A 28-year-old female with Graves' disease is 6 weeks pregnant and
experiencing severe hyperthyroidism symptoms. She requests medication
to control her symptoms. What is the guideline-based pharmacologic
approach?
o A. Methimazole is preferred throughout pregnancy due to lower
hepatotoxicity risk.
o B. Propylthiouracil (PTU) is preferred in the first trimester due to
lower risk of embryopathy.
o C. Radioactive Iodine (I-131) is safe as the fetal thyroid is inactive
until week 20.
o D. No treatment is needed; hyperthyroidism is protective in
pregnancy and does not cross the placenta.
Answer: B. Propylthiouracil (PTU) is preferred in the first trimester
due to lower risk of embryopathy.
• • • Rotation: Teratogenicity Risk Stratification.
o First Trimester: PTU. Methimazole is associated with
"Methimazole Embryopathy" (Choanal atresia, aplasia cutis). The
FDA and ATA recommend PTU for the first 16 weeks.
o Second/Third Trimester: Switch to Methimazole. PTU carries
a Black Box Warning for severe hepatotoxicity, which is more
dangerous to the mother later in pregnancy.
o Option A is wrong; Methimazole is avoided early. Option C is
wrong; RAI is ABSOLUTELY contraindicated in pregnancy
(ablates fetal thyroid).
pg. 4
